Search Results

Medison Pharma and Alnylam Pharmaceuticals, Inc. announced a further expansion of their existing partnership in Central & Eastern Europe and Israel, to also include selected markets in LATAM and APAC and additional international markets.

Medison Pharma announced their exclusive multi-national agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, to commercialize Libtayo®, a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in select European markets and additional markets around the world.

Essential Pharma announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.

Ipsen and Medison Pharma are pleased to announce the Health Canada approval for Bylvay™ for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis, a progressive and life-threatening liver disease.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

Medison Pharma, a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is proud to announce the joining of Sarah Otten, in the role of VP, GM of Medison’s Americas Region.

Alnylam Pharmaceuticals, Inc. and Medison Pharma have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.